Press release
In-Depth Analysis of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market: Growth Opportunities, Key Trends, and Forecast 2025-2034
Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Share
The rise in ovarian cancer cases is expected to drive the growth of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer's growth is attributed to genetic, environmental, and aging factors. PARP inhibitors target DNA repair mechanisms, especially in patients with BRCA mutations, improving treatment outcomes. In February 2024, the World Ovarian Cancer Coalition projected a significant increase in ovarian cancer-related deaths by 2050. This increasing prevalence is contributing to the demand for PARP inhibitors.
Get Your Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report Here:
https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitor-global-market-report
What growth opportunities are expected to drive the poly adp-ribose polymerase (parp) inhibitor market's CAGR through 2034?
The poly ADP-ribose polymerase (PARP) inhibitor market has grown rapidly in recent years. It will increase from $8.39 billion in 2024 to $9.41 billion in 2025, at a CAGR of 12.1%. The growth is driven by clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy.
The poly ADP-ribose polymerase (PARP) inhibitor market is expected to grow to $14.67 billion by 2029, with a CAGR of 11.7%. Growth is driven by expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends include precision medicine, immunotherapy advancements, targeted therapies, AI in drug discovery, and patient-centric healthcare.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp
What are the emerging trends shaping the future of the poly adp-ribose polymerase (parp) inhibitor market?
Companies in the poly ADP-ribose polymerase (PARP) inhibitor market are focusing on generic PARP inhibitors to offer customized treatments for cancer patients with specific genetic mutations. Generic PARP inhibitors block the activity of the PARP enzyme. In March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib under the IBYRA brand. This PARP inhibitor is aimed at enhancing cancer treatment accessibility, particularly for patients with HRD-positive or BRCA mutations, and helps delay disease progression in breast, ovarian, prostate, and pancreatic cancers.
Which growth-oriented segments of the poly adp-ribose polymerase (parp) inhibitor market are leading the industry's development?
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented -
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637
What regions are leading the charge in the poly adp-ribose polymerase (parp) inhibitor market?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What companies are at the forefront of innovation in the poly adp-ribose polymerase (parp) inhibitor market?
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp
What Is Covered In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report?
•Market Size Forecast: Examine the poly adp-ribose polymerase (parp) inhibitor market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the poly adp-ribose polymerase (parp) inhibitor market for a structured understanding.
•Key Players Overview: Analyze major players in the poly adp-ribose polymerase (parp) inhibitor market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the poly adp-ribose polymerase (parp) inhibitor market.
•Segment Contributions: Evaluate how different segments drive overall growth in the poly adp-ribose polymerase (parp) inhibitor market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the poly adp-ribose polymerase (parp) inhibitor market.
•Industry Challenges: Identify potential risks and obstacles affecting the poly adp-ribose polymerase (parp) inhibitor market.
•Competitive Landscape: Review strategic developments in the poly adp-ribose polymerase (parp) inhibitor market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release In-Depth Analysis of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market: Growth Opportunities, Key Trends, and Forecast 2025-2034 here
News-ID: 3931901 • Views: …
More Releases from The Business Research Company
Leading Companies Fueling Growth and Innovation in the Energy Efficient Windows …
The energy efficient windows sector is poised for steady expansion as global efforts to promote sustainable construction and energy savings ramp up. With innovations in technology and increasing demand from both new building projects and renovations, the industry is set to experience consistent growth through the end of the decade. Let's explore the market size outlook, key players, emerging trends, and segmentation details to understand the future trajectory of this…
Future Perspectives: Key Trends Shaping the Cutlery and Hand Tools Market Until …
The cutlery and hand tools sector is on a steady upward path, driven by evolving consumer preferences and expanding commercial needs. As both professional and home users seek higher quality and more versatile tools, this market is set to experience notable growth and innovation in the coming years. Let's explore the current market size projections, leading companies, key trends, and the detailed segmentation shaping this industry's future.
Projected Market Size of…
Emerging Sub-Segments Transforming the Concrete Materials Market Landscape
The concrete materials market is set to experience steady expansion over the coming years, driven by several evolving trends and increasing demand across various construction sectors. As sustainable building practices gain traction and urban infrastructure projects accelerate, this market is positioned for consistent growth through 2030. Let's explore the current market size, leading companies, emerging trends, and key segments shaping the future of concrete materials.
Forecasted Growth and Market Size of…
Market Trend Analysis: The Impact of Recent Innovations on the Coated Glass Mark …
Understanding the coated glass market reveals a promising future driven by innovation and expanding applications. As industries push toward smarter, more energy-efficient solutions, coated glass is becoming increasingly essential across various sectors. Let's explore the market's valuation, key players, emerging trends, and segmented landscape to grasp its growth trajectory and driving forces.
Forecasted Market Valuation and Growth Outlook in the Coated Glass Market
The coated glass market is set for significant…
More Releases for PARP
PARP Inhibitors Market Report- Expansive Coverage on the Profit Sources
The global PARP Inhibitors Market Size is valued at USD 3.8 Billion in 2024 and is predicted to reach USD 15.5 Billion by the year 2034 at a 15.2% CAGR during the forecast period for 2025-2034.
Request For Free Sample Pages :
https://www.insightaceanalytic.com/request-sample/1169
Poly (ADP-ribose) polymerase (PARP) inhibitors target a family of 17 enzymes responsible for catalyzing the formation of ADP-ribose chains (PAR chains) and transferring them to specific target proteins. These enzymes…
PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8…
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
